ReviewPharmaceutical research2012
An overview of tubulin inhibitors that interact with the colchicine binding site.
Review in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04696848 (A Phase I Study to Determine the Efficacy and Safety of CKD-516 Tablet Combined With Durvalumab), which is not on this map. Cited by 286 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study to Determine the Efficacy and Safety of CKD-516 Tablet Combined With Durvalumab(MEDI4736) in Patient Refractory Solid Tumors
Who cites it
286 citing papers in PubMed.
- A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma.The Kaohsiung journal of medical sciences · 2021Trial
- Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis.Cancer letters · 2026Review
- Quantum mechanical and molecular dynamics insights into the binding mechanism of tubulin-stabilizing agents at the taxol site of β-tubulin.Journal of molecular modeling · 2026Article
- Innate immune sensors of inflammasomes and PANoptosomes: structural-mechanistic insights and therapeutic implications.Cell research · 2026Review
- Synthesis of 1,3,5-Triazine-Indole Conjugates as Broad-Spectrum Coronavirus Entry Inhibitors.ChemMedChem · 2026Article
- General Assessment of Indole Derivatives and Wnt Pathway as Potential Key Factors Against Various Diseases, with Particular Emphasis on Thyroid Tumors.International journal of molecular sciences · 2026Review
- One-dimensional palladium MOF as VEGFR2 and colchicine binding inhibitors with potential anticancer and anti-inflammatory activities: synthesis and molecular investigation.Scientific reports · 2026Article
- Generation of Donor/Donor Copper Carbenes through Copper-Catalyzed Cycloisomerization/Oxidation of Vinyl-Allenes: Constructing Functionalized Cyclopentenones.Chemistry, an Asian journal · 2026Article
- PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity.Molecular cancer therapeutics · 2026Article
- Targeting colorectal cancer with pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides: comprehensive in vitro evaluation.Scientific reports · 2026Article
- Design, synthesis, and antiproliferative activity of novel thiazole-based derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.RSC advances · 2026Article
- Article
- Review
- Discovery of a Novel Coumarin/Thiazole Chalcone Hybrid as a Potent Dual Inhibitor of Tubulin and Carbonic Anhydrases IX & XII with Promising Anti-Proliferative Activity.Molecules (Basel, Switzerland) · 2026Article
- Harnessing endophytes and Multi-Omics for sustainable Colchicine biosynthesis.World journal of microbiology & biotechnology · 2026Review
- Design, synthesis, and biological evaluation of sulfonamide-functionalized pyridine carbothioamides as potent tubulin-targeting anticancer agents.RSC medicinal chemistry · 2026Article
- Synthesis and anti-proliferative activity of new E7010 tethered urea congeners as potential tubulin inhibitors and apoptosis inducers.RSC advances · 2026Article
- REV1 Loss Triggers a G2/M Cell-Cycle Arrest Through Dysregulation of Mitotic Regulators.Genes · 2025Article
- Technological advances in visualizing and rewiring microtubules during plant development.Journal of experimental botany · 2025Review
226 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tubulin dynamics is a promising target for new chemotherapeutic agents. The colchicine binding site is one of the most important pockets for potential tubulin polymerization destabilizers. Colchicine binding site inhibitors (CBSI) exert their biological effects by inhibiting tubulin assembly and suppressing microtubule formation. A large number of molecules interacting with the colchicine binding site have been designed and synthesized with significant structural diversity. CBSIs have been modified as to chemical structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers. CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin. The present review is a synopsis of compounds that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.